Drug Development/R&D

The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this post summarises their activity.

On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology Initiative (POI) as part of a wider research project being undertaken by OHE.

This study provides an analytical framework, drawing on production function theory, to identify and quantify the determinants of relative effectiveness and sources of variation in the relative effectiveness of treatments between populations and healthcare systems.

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines

OHE’s Yan Feng and Jorge Mestre-Ferrandiz have co-authored a new publication on quantifying the spillovers between public and private sector biomedical and health research and development funding in the UK.

OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.

Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for Imperial College and the UK Department of Health.

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.

Pages

Subscribe to RSS - Drug Development/R&D